This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Hirokazu Okayama: Innovator in Lung Cancer Biomarkers
Introduction
Hirokazu Okayama is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of cancer research, particularly in the identification of biomarkers for early-stage lung cancer. His work has the potential to improve prognostic assessments and treatment strategies for patients.
Latest Patents
Hirokazu Okayama holds a patent titled "Expression protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer." This invention provides novel biomarkers, specifically four genes: BRCA1, HIF1A, DLC1, and XPO1, either alone or in combination with miR-21. These biomarkers are crucial for early detection and classification of lung cancer, which can lead to better patient outcomes.
Career Highlights
He is currently associated with the United States of America, as represented by the Secretary, Department of Health and Human Services. His role in this esteemed organization underscores his commitment to advancing public health through innovative research.
Collaborations
Hirokazu Okayama has collaborated with notable colleagues, including Curtis C Harris and Aaron Joseph Schetter. These partnerships have likely enhanced the depth and impact of his research in the field of oncology.
Conclusion
Hirokazu Okayama's contributions to lung cancer research through his innovative patent highlight the importance of biomarkers in early detection and treatment. His work exemplifies the critical role of inventors in advancing medical science and improving patient care.